FibroGen Securities Litigation Settlement
This settlement is closed to new claims. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
FibroGen and its executives allegedly misrepresented the safety profile and Phase III trial results of its anti-anemia drug Roxadustat, which the company had submitted for FDA approval in December 2019. Investors claim FibroGen's stock price was artificially inflated due to these false statements and declined when the truth was revealed. Defendants deny all wrongdoing.
Do you qualify?
Anyone who purchased or acquired FibroGen, Inc. securities, including options, between December 20, 2018 through July 15, 2021. Excluded are defendants, officers, directors, their immediate family members, and entities they owned or controlled.
How to file
Contact the Claims Administrator at (877) 595-0137, email Info@FibroGenSecuritiesLitigation.com, or visit the settlement website. The claims filing period has closed; distributions are now occurring on a rolling basis for approved claimants.
In the news
Headlines via NewsAPI. ClaimWatch isn't affiliated with these publications.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Tattooed Chef Securities Settlement
Tattooed Chef, Inc. faced a securities lawsuit alleging that purchasers of the company's common stock were damaged. The defendant has agreed to settle all claims in the action for $4,750,000 in cash without admitting wrongdoing.
Estée Lauder Securities Settlement
Estée Lauder is settling securities litigation relating to alleged damages to investors who purchased or acquired publicly traded common stock of The Estée Lauder Companies Inc. during the class period. The defendant has not admitted wrongdoing in this settlement.
E-Commerce China Dangdang Securities Settlement
E-Commerce China Dangdang, Inc. was involved in a take-private transaction (merger) that closed on September 20, 2016. Shareholders who held American Depositary Shares during the Class Period claim they were harmed by undisclosed information related to the Company's take-private transaction. The defendant has agreed to settle these securities claims without admitting wrongdoing.
Evolv Technologies Holdings Securities Settlement
Investors purchased publicly traded common stock of Evolv Technologies Holdings Inc. during a specific period and are entitled to compensation from a securities class action settlement. The page does not explicitly state what wrongdoing Evolv allegedly committed.